# ClinicalTrials.gov record NCT05478707

> PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05478707-dulaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-12
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05478707-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05478707-dulaglutide-v1.json
- Content SHA-256: `5af4a24dcdaeaaef5e12009858f5b7519be942ae2f20986399ad9dedee99d1c9`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05478707 ([`ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c`](#source-ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c`](#source-ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c`](#source-ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c`](#source-ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c))

## Sources

<a id="source-ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c"></a>
- **ClinicalTrials.gov record NCT05478707 · retained source version 2026-08-12:d59fb7a72a7cb11dcfb34bfa1b0c4287bf0d0f7193a97a67cbc82f04cdfa44e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05478707) (`ctg-observation-nct05478707-2026-08-12-d59fb7a72a7c`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05478707." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05478707-dulaglutide-v1.json SHA-256: 5af4a24dcdaeaaef5e12009858f5b7519be942ae2f20986399ad9dedee99d1c9.